Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Biol Chem ; 289(11): 7362-73, 2014 Mar 14.
Artículo en Inglés | MEDLINE | ID: mdl-24469445

RESUMEN

Arabinanases (ABNs, EC 3.2.1.99) are promising catalysts for environmentally friendly biomass conversion into energy and chemicals. These enzymes catalyze the hydrolysis of the α-1,5-linked L-arabinofuranoside backbone of plant cell wall arabinans releasing arabino-oligosaccharides and arabinose, the second most abundant pentose in nature. In this work, new findings about the molecular mechanisms governing activation, functional differentiation, and catalysis of GH43 ABNs are presented. Biophysical, mutational, and biochemical studies with the hyperthermostable two-domain endo-acting ABN from Thermotoga petrophila (TpABN) revealed how some GH43 ABNs are activated by calcium ions via hyperpolarization of the catalytically relevant histidine and the importance of the ancillary domain for catalysis and conformational stability. On the other hand, the two GH43 ABNs from rumen metagenome, ARN2 and ARN3, presented a calcium-independent mechanism in which sodium is the most likely substituent for calcium ions. The crystal structure of the two-domain endo-acting ARN2 showed that its ability to efficiently degrade branched substrates is due to a larger catalytic interface with higher accessibility than that observed in other ABNs with preference for linear arabinan. Moreover, crystallographic characterization of the single-domain exo-acting ARN3 indicated that its cleavage pattern producing arabinose is associated with the chemical recognition of the reducing end of the substrate imposed by steric impediments at the aglycone-binding site. By structure-guided rational design, ARN3 was converted into a classical endo enzyme, confirming the role of the extended Arg(203)-Ala(230) loop in determining its action mode. These results reveal novel molecular aspects concerning the functioning of GH43 ABNs and provide new strategies for arabinan degradation.


Asunto(s)
Arabinosa/química , Proteínas Bacterianas/metabolismo , Catálisis , Glicósido Hidrolasas/metabolismo , Bacilos Gramnegativos Anaerobios Rectos, Curvos y Espirales/enzimología , Secuencia de Aminoácidos , Animales , Sitios de Unión , Biotecnología , Calcio/química , Bovinos , Clonación Molecular , Cristalografía por Rayos X , Análisis Mutacional de ADN , Hidrólisis , Iones/química , Cinética , Ligandos , Metagenoma , Metales/química , Modelos Moleculares , Datos de Secuencia Molecular , Mutagénesis , Ingeniería de Proteínas , Estructura Terciaria de Proteína , Rumen/microbiología , Homología de Secuencia de Aminoácido , Solventes/química
2.
J Biol Chem ; 288(47): 34131-34145, 2013 Nov 22.
Artículo en Inglés | MEDLINE | ID: mdl-24097982

RESUMEN

Myosin V (MyoV) motors have been implicated in the intracellular transport of diverse cargoes including vesicles, organelles, RNA-protein complexes, and regulatory proteins. Here, we have solved the cargo-binding domain (CBD) structures of the three human MyoV paralogs (Va, Vb, and Vc), revealing subtle structural changes that drive functional differentiation and a novel redox mechanism controlling the CBD dimerization process, which is unique for the MyoVc subclass. Moreover, the cargo- and motor-binding sites were structurally assigned, indicating the conservation of residues involved in the recognition of adaptors for peroxisome transport and providing high resolution insights into motor domain inhibition by CBD. These results contribute to understanding the structural requirements for cargo transport, autoinhibition, and regulatory mechanisms in myosin V motors.


Asunto(s)
Miosina Tipo V/química , Sitios de Unión , Transporte Biológico Activo/fisiología , Humanos , Miosina Tipo V/genética , Miosina Tipo V/metabolismo , Peroxisomas/química , Peroxisomas/genética , Peroxisomas/metabolismo , Estructura Cuaternaria de Proteína , Estructura Terciaria de Proteína , Homología Estructural de Proteína
3.
Structure ; 32(6): 812-823.e4, 2024 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-38513659

RESUMEN

Mollusk hemocyanins, among the largest known proteins, are used as immunostimulants in biomedical and clinical applications. The hemocyanin of the Chilean gastropod Concholepas concholepas (CCH) exhibits unique properties, which makes it safe and effective for human immunotherapy, as observed in animal models of bladder cancer and melanoma, and dendritical cell vaccine trials. Despite its potential, the structure and amino acid sequence of CCH remain unknown. This study reports two sequence fragments of CCH, representing three complete functional units (FUs). We also determined the high-resolution (1.5 Å) X-ray crystal structure of an "FU-g type" from the CCHB subunit. This structure enables in-depth analysis of chemical interactions at the copper-binding center and unveils an unusual, truncated N-glycosylation pattern. These features are linked to eliciting more robust immunological responses in animals, offering insights into CCH's enhanced immunostimulatory properties and opening new avenues for its potential applications in biomedical research and therapies.


Asunto(s)
Secuencia de Aminoácidos , Hemocianinas , Modelos Moleculares , Hemocianinas/química , Hemocianinas/inmunología , Animales , Cristalografía por Rayos X , Glicosilación , Sitios de Unión , Gastrópodos/inmunología , Gastrópodos/química , Cobre/química , Moluscos/inmunología , Unión Proteica
4.
Acta Crystallogr D Struct Biol ; 77(Pt 4): 522-533, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33825712

RESUMEN

The plant-specific class XI myosins (MyoXIs) play key roles at the molecular, cellular and tissue levels, engaging diverse adaptor proteins to transport cargoes along actin filaments. To recognize their cargoes, MyoXIs have a C-terminal globular tail domain (GTD) that is evolutionarily related to those of class V myosins (MyoVs) from animals and fungi. Despite recent advances in understanding the functional roles played by MyoXI in plants, the structure of its GTD, and therefore the molecular determinants for cargo selectivity and recognition, remain elusive. In this study, the first crystal structure of a MyoXI GTD, that of MyoXI-K from Arabidopsis thaliana, was elucidated at 2.35 Šresolution using a low-identity and fragment-based phasing approach in ARCIMBOLDO_SHREDDER. The results reveal that both the composition and the length of the α5-α6 loop are distinctive features of MyoXI-K, providing evidence for a structural stabilizing role for this loop, which is otherwise carried out by a molecular zipper in MyoV GTDs. The crystal structure also shows that most of the characterized cargo-binding sites in MyoVs are not conserved in plant MyoXIs, pointing to plant-specific cargo-recognition mechanisms. Notably, the main elements involved in the self-regulation mechanism of MyoVs are conserved in plant MyoXIs, indicating this to be an ancient ancestral trait.


Asunto(s)
Proteínas de Arabidopsis/química , Arabidopsis/metabolismo , Modelos Moleculares , Miosinas/química , Conformación Proteica , Sitios de Unión , Dominios Proteicos
5.
Biochim Biophys Acta Gen Subj ; 1864(7): 129597, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32156582

RESUMEN

The arginine repressor (ArgR) regulates the expression of genes involved in arginine biosynthesis. Upon attaining a threshold concentration of arginine in the cytoplasm, the trimeric C-terminal domain of ArgR binds three arginines in a shallow surface cleft and subsequently hexamerizes forming a dimer of trimers containing six Arg co-repressor molecules which are buried at the subunit interfaces. The N-terminal domains of this complex bind to the DNA promoter thereby interrupting the transcription of the genes related to Arg biosynthesis. The crystal structures of the wild type and mutant Pro115Gln ArgR from Corynebacterium pseudotuberculosis determined at 1.7 Å demonstrate that a single amino acid substitution switches co-repressor specificity from Tyr to Arg. Molecular dynamics simulations indicate that the first step, i.e., the binding of the co-repressor, occurs in the trimeric state and that Pro115Gln ArgR preferentially binds Arg. It was also shown that, in Pro115 ArgR hexamers, the concomitant binding of sodium ions shifts selectivity to Tyr. Structural data combined with phylogenetic analyses of ArgR from C. pseudotuberculosis suggest that substitutions in the binding pocket at position 115 may alter its specificity for amino acids and that the length of the protein interdomain linker can provide further functional flexibility. These results support the existence of alternative ArgR regulatory mechanisms in this pathogenic bacterium.


Asunto(s)
Proteínas Bacterianas/genética , Corynebacterium pseudotuberculosis/genética , Filogenia , Proteínas Represoras/genética , Transcripción Genética , Secuencia de Aminoácidos/genética , Arginina/biosíntesis , Arginina/genética , Sitios de Unión , ADN Bacteriano/genética , Regulación Bacteriana de la Expresión Génica , Mutación/genética , Regiones Promotoras Genéticas/genética , Unión Proteica/genética
6.
FEBS Open Bio ; 9(9): 1589-1602, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31314152

RESUMEN

Ragulator is a pentamer composed of p18, MP1, p14, C7orf59, and hepatitis B virus X-interacting protein (HBXIP; LAMTOR 1-5) which acts as a lysosomal scaffold of the Rag GTPases in the amino acid sensitive branch of TORC1 signaling. Here, we present the crystal structure of human HBXIP-C7orf59 dimer (LAMTOR 4/5) at 2.9 Å and identify a phosphorylation site on C7orf59 which modulates its interaction with p18. Additionally, we demonstrate the requirement of HBXIP-C7orf59 to stabilize p18 and allow further binding of MP1-p14. The structure of the dimer revealed an unfolded N terminus in C7orf59 (residues 1-15) which was shown to be essential for p18 binding. Full-length p18 does not interact stably with MP1-p14 in the absence of HBXIP-C7orf59, but deletion of p18 residues 108-161 rescues MP1-p14 binding. C7orf59 was phosphorylated by protein kinase A (PKA) in vitro and mutation of the conserved Ser67 residue to aspartate prevented phosphorylation and negatively affected the C7orf59 interaction with p18 both in cell culture and in vitro. C7orf59 Ser67 was phosphorylated in human embryonic kidney 293T cells. PKA activation with forskolin induced dissociation of p18 from C7orf59, which was prevented by the PKA inhibitor H-89. Our results highlight the essential role of HBXIP-C7orf59 dimer as a nucleator of pentameric Ragulator and support a sequential model of Ragulator assembly in which HBXIP-C7orf59 binds and stabilizes p18 which allows subsequent binding of MP1-p14.


Asunto(s)
Factores de Intercambio de Guanina Nucleótido/química , Factores de Intercambio de Guanina Nucleótido/metabolismo , Complejos Multiproteicos/química , Complejos Multiproteicos/metabolismo , Células Cultivadas , Cristalografía por Rayos X , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Células HEK293 , Humanos , Modelos Moleculares , Fosforilación , Conformación Proteica
7.
Biosci Rep ; 39(3)2019 03 29.
Artículo en Inglés | MEDLINE | ID: mdl-30733278

RESUMEN

Myosin Va (MyoVa) is an actin-based molecular motor that plays key roles in the final stages of secretory pathways, including neurotransmitter release. Several studies have addressed how MyoVa coordinates the trafficking of secretory vesicles, but why this molecular motor is found in exosomes is still unclear. In this work, using a yeast two-hybrid screening system, we identified the direct interaction between the globular tail domain (GTD) of MyoVa and four protein components of exosomes: the WD repeat-containing protein 48 (WDR48), the cold shock domain-containing protein E1 (CSDE1), the tandem C2 domain-containing protein 1 (TC2N), and the enzyme spermine synthase (SMS). The interaction between the GTD of MyoVa and SMS was further validated in vitro and displayed a Kd in the low micromolar range (3.5 ± 0.5 µM). SMS localized together with MyoVa in cytoplasmic vesicles of breast cancer MCF-7 and neuroblastoma SH-SY5Y cell lines, known to produce exosomes. Moreover, MYO5A knockdown decreased the expression of SMS gene and rendered the distribution of SMS protein diffuse, supporting a role for MyoVa in SMS expression and targeting.


Asunto(s)
Vesículas Citoplasmáticas/metabolismo , Exosomas/metabolismo , Cadenas Pesadas de Miosina/metabolismo , Miosina Tipo V/metabolismo , Espermina Sintasa/metabolismo , Sitios de Unión , Línea Celular Tumoral , Células Cultivadas , Exosomas/genética , Fibroblastos/citología , Fibroblastos/metabolismo , Regulación de la Expresión Génica , Humanos , Células MCF-7 , Cadenas Pesadas de Miosina/genética , Miosina Tipo V/genética , Unión Proteica , Transporte de Proteínas , Interferencia de ARN , Espermina Sintasa/genética , Técnicas del Sistema de Dos Híbridos
8.
Prostaglandins Other Lipid Mediat ; 80(3-4): 123-35, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16939877

RESUMEN

Lipoxin A4 (LXA4) is a lipid mediator that plays an important role in the resolution of inflammation. However, the role of LXA4 and aspirin (ASA)-triggered lipoxins (ATLs) in inflammatory edema formation remains unclear. Here, we investigated the inhibitory role played by LXA4 in the carrageenan-induced and other inflammatory mediator-induced edematogenic response in mice, and also assessed the role of ATLs in the anti-edematogenic action of aspirin. Our results showed that LXA4 (1-20 ng/paw or 5 microg/kg i.p.) was effective in inhibiting carrageenan-induced paw edema from 30 min to 2 h. LXA4 (10 ng/paw) was also able to acutely inhibit PAF-, histamine-, PGE2- or bradykinin-induced paw edema, as well as the PAF-induced myeloperoxidase activity increase in the paws. Likewise, LXA4 (10 ng/cavity) also inhibited the pleural edema triggered by histamine (1h), and this response was not followed by leukocyte accumulation. Of note, the lipoxin receptor (ALX-r) antagonist Boc2 (butoxycarbonyl-Phe-Leu-Phe-Leu-Phe, 200 ng/paw) significantly reverted the anti-edematogenic effect of ASA (300 mg/kg p.o.) against carrageenan, PAF, PGE2 and BK, without affecting the anti-edematogenic action caused by indomethacin (3 mg/kg i.p.) in the carrageenan-induced paw edema. Collectively, our results demonstrate for the first time that LXA4 displays an acute and rapid onset anti-edematogenic activity that does not discriminate among different pro-inflammatory stimuli, an effect that is most likely independent of its action on the leukocyte influx. Finally, the present study demonstrates that ATLs exert a very important role in the acute anti-edematogenic action of ASA.


Asunto(s)
Aspirina/farmacología , Edema/prevención & control , Lipoxinas/farmacología , Enfermedad Aguda , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Aspirina/administración & dosificación , Bradiquinina/administración & dosificación , Bradiquinina/farmacología , Carragenina , Dinoprostona/administración & dosificación , Dinoprostona/farmacología , Relación Dosis-Respuesta a Droga , Edema/inducido químicamente , Edema/patología , Pie/patología , Miembro Posterior/efectos de los fármacos , Miembro Posterior/patología , Histamina/administración & dosificación , Histamina/farmacología , Indometacina/administración & dosificación , Indometacina/farmacología , Inyecciones Intraperitoneales , Leucocitos/efectos de los fármacos , Leucocitos/patología , Lipoxinas/administración & dosificación , Masculino , Ratones , Infiltración Neutrófila/efectos de los fármacos , Oligopéptidos/administración & dosificación , Oligopéptidos/farmacología , Factor de Activación Plaquetaria/administración & dosificación , Factor de Activación Plaquetaria/farmacología , Pleuresia/inducido químicamente , Pleuresia/patología , Pleuresia/prevención & control , Receptores de Lipoxina/antagonistas & inhibidores
9.
Eur J Pharmacol ; 698(1-3): 413-20, 2013 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-23099255

RESUMEN

Inflammation underlies the development and progression of a number of skin disorders including psoriasis, atopic dermatitis and cancer. Therefore, novel antiinflammatory agents are of great clinical interest for prevention and treatment of these conditions. Herein, we demonstrated the underlying molecular mechanisms of the antiinflammatory activity of euphol, a tetracyclic triterpene isolated from the sap of Euphorbia tirucalli, in skin inflammation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in mice. Topical application of euphol (100 µg/ear) significantly inhibited TPA-induced ear edema and leukocyte influx through the reduction of keratinocyte-derived chemokine (CXCL1/KC) and macrophage inflammatory protein (MIP)-2 levels. At the intracellular level, euphol reduced TPA-induced extracellular signal-regulated protein kinase (ERK) activation and cyclooxygenase-2 (COX-2) upregulation. These effects were associated with euphol's ability to prevent TPA-induced protein kinase C (PKC) activation, namely PKCα and PKCδ isozymes. Our data indicate that topical application of euphol markedly inhibits the inflammatory response induced by TPA. Thus, euphol represents a promising agent for the management of skin diseases with an inflammatory component.


Asunto(s)
Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Lanosterol/análogos & derivados , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Proteína Quinasa C/metabolismo , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/tratamiento farmacológico , Acetato de Tetradecanoilforbol/efectos adversos , Administración Tópica , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Ciclooxigenasa 2/metabolismo , Edema/inducido químicamente , Edema/tratamiento farmacológico , Edema/inmunología , Edema/patología , Activación Enzimática/efectos de los fármacos , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Inflamación/patología , Lanosterol/administración & dosificación , Lanosterol/farmacología , Lanosterol/uso terapéutico , Leucocitos/efectos de los fármacos , Leucocitos/inmunología , Masculino , Ratones , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/patología , Regulación hacia Arriba/efectos de los fármacos
10.
Peptides ; 37(2): 216-24, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22868213

RESUMEN

Endothelial dysfunction has been implicated in portal vein obstruction, a condition responsible for major complications in chronic portal hypertension. Increased vascular tone due to disruption of endothelial function has been associated with an imbalance in the equilibrium between endothelium-derived relaxing and contracting factors. Herein, we assessed underlying mechanisms by which expression of bradykinin B(1) receptor (B(1)R) is induced in the endothelium and how its stimulation triggers vasoconstriction in the rat portal vein. Prolonged in vitro incubation of portal vein resulted in time- and endothelium-dependent expression of B(1)R and cyclooxygenase-2 (COX-2). Inhibition of protein kinase C (PKC) or phosphatidylinositol 3-kinase (PI3K) significantly reduced expression of B(1)R through the regulation of transcription factors, activator protein-1 (AP-1) and cAMP response element-binding protein (CREB). Moreover, pharmacological studies showed that B(1)R-mediated portal vein contraction was reduced by COX-2, but not COX-1, inhibitors. Notably, activation of endothelial B(1)R increased phospholipase A(2)/COX-2-derived thromboxane A(2) (TXA(2)) levels, which in turn mediated portal vein contraction through binding to TXA(2) receptors expressed in vascular smooth muscle cells. These results provide novel molecular mechanisms involved in the regulation of B(1)R expression and identify a critical role for the endothelial B(1)R in the modulation of portal vein vascular tone. Our study suggests a potential role for B(1)R antagonists as therapeutic tools for diseases where portal hypertension may be involved.


Asunto(s)
Bradiquinina/farmacología , Endotelio/metabolismo , Vena Porta/efectos de los fármacos , Receptor de Bradiquinina B1/metabolismo , Vasoconstricción/efectos de los fármacos , Animales , Bradiquinina/análogos & derivados , Relación Dosis-Respuesta a Droga , Masculino , Vena Porta/metabolismo , Ratas , Ratas Wistar , Receptor de Bradiquinina B1/biosíntesis , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA